Phase III studies to investigate survodutide for people living with obesity and overweight, with and without diabetes, cardiovascular disease and chronic kidney disease
October 05, 2023 05:53 ET
|
Zealand Pharma
Phase III studies to investigate survodutide for people living with obesity and overweight, with and without diabetes, cardiovascular disease and chronic kidney disease Press release – No. 12 /...
Total number of shares and voting rights in Zealand Pharma at September 29, 2023
September 29, 2023 11:15 ET
|
Zealand Pharma
Company announcement – No. 36 / 2023 Total number of shares and voting rights in Zealand Pharma at September 29, 2023 Copenhagen, Denmark, September 29, 2023 – Zealand Pharma A/S (“Zealand”)...
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
September 14, 2023 16:30 ET
|
Zealand Pharma
Company announcement – No. 35 / 2023 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons ...
Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants
September 14, 2023 16:00 ET
|
Zealand Pharma
Company announcement – No. 34 / 2023 Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants Copenhagen, Denmark, September 14, 2023 – Zealand Pharma A/S...
SAVE THE DATE: Zealand Pharma to host Obesity R&D Event in London on December 5, 2023
September 08, 2023 05:00 ET
|
Zealand Pharma
Press release – No. 11 / 2023 SAVE THE DATE: Zealand Pharma to host Obesity R&D Event in London on December 5, 2023 Copenhagen, Denmark, September 8, 2023 – Zealand Pharma A/S (Nasdaq: ZEAL)...
Zealand Pharma to participate in upcoming healthcare conferences in September 2023
September 07, 2023 11:00 ET
|
Zealand Pharma
Press release – No. 10 / 2023 Zealand Pharma to participate in upcoming healthcare conferences in September 2023 Copenhagen, Denmark, September 7, 2023 – Zealand Pharma A/S (Nasdaq: ZEAL)...
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
August 31, 2023 11:35 ET
|
Zealand Pharma
Company announcement – No. 33 / 2023 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons ...
Total number of shares and voting rights in Zealand Pharma at August 31, 2023
August 31, 2023 11:30 ET
|
Zealand Pharma
Company announcement – No. 32 / 2023 Copenhagen, Denmark, August 31, 2023 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on...
Zealand Pharma announces designation of priority review by the US FDA for dasiglucagon in congenital hyperinsulinism
August 30, 2023 01:33 ET
|
Zealand Pharma
Company announcement – No. 31 / 2023 Zealand Pharma announces designation of priority review by the US FDA for dasiglucagon in congenital hyperinsulinism US FDA has granted priority review...
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
August 25, 2023 10:45 ET
|
Zealand Pharma
Company announcement – No. 30 / 2023 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons ...